Go to the profile of Tilt Biotherapeutics

Tilt Biotherapeutics

 

About Tilt Biotherapeutics

TILT Biotherapeutics, founded in 2013, is a leading company globally working in the area of enabling tumor T-cell therapy with oncolytic viruses. The company’s patented technology is used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy. TILT has secured almost 10M€ in funding and is now setting up phase I clinical trials, where its approach is further evaluated in cancer patients.

Therapeutic Areas

Oncology

Technologies

Biologics Nucleic acids Vaccines

Company Type

Biotechnology – Therapeutics

State of Ownership

Private

Sponsorship Group

Networker

Topics

Topics contributed to:

Oncology

Editions participated in:

March 2017